Charles Williams Biography and Net Worth

COO of Surrozen

Charles Williams brings 20 years of biopharmaceutical industry experience across various leadership positions in strategy, operations, finance and corporate development. He most recently headed corporate development at Jazz Pharmaceuticals plc. Previously, he held various corporate development and finance roles at MAP Pharmaceuticals (acquired by Allergan) and CV Therapeutics (acquired by Gilead). He started his career in biopharmaceutical consulting and investment banking. Mr. Williams earned a B.A. in economics from Cornell University.

What is Charles O. Williams' net worth?: The estimated net worth of Charles O. Williams is at least $387.60 thousand as of May 4th, 2026. Mr. Williams owns 16,571 shares of Surrozen stock worth more than $387,596 as of June 14th. This net worth approximation does not reflect any other assets that Mr. Williams may own. Learn More about Charles O. Williams' net worth.
How do I contact Charles O. Williams?: The corporate mailing address for Mr. Williams and other Surrozen executives is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. Surrozen can also be reached via phone at 650-489-9000 and via email at [email protected]. Learn More on Charles O. Williams' contact information.
Has Charles O. Williams been buying or selling shares of Surrozen?: In the last ninety days, Charles O. Williams has sold $67,859.88 of Surrozen stock. Most recently, Charles O. Williams sold 2,036 shares of the business's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $33.33, for a transaction totalling $67,859.88. Following the completion of the sale, the chief operating officer now directly owns 16,571 shares of the company's stock, valued at $552,311.43. Learn More on Charles O. Williams' trading history.
Who are Surrozen's active insiders?: Surrozen's insider roster includes Tim Kutzkey (Director), Yang Li (VP), Craig Parker (CEO), and Charles Williams (COO). Learn More on Surrozen's active insiders.
Are insiders buying or selling shares of Surrozen?: During the last year, Surrozen insiders bought shares 28 times. They purchased a total of 1,033,505 shares worth more than $16,849,523.68. During the last year, insiders at the sold shares 5 times. They sold a total of 10,828 shares worth more than $324,770.60. The most recent insider tranaction occured on May, 4th when VP Yang Li sold 1,584 shares worth more than $52,794.72. Insiders at Surrozen own 31.7% of the company. Learn More about insider trades at Surrozen.
Information on this page was last updated on 5/4/2026.

Charles O. Williams Insider Trading History at Surrozen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/4/2026	Sell	2,036	$33.33	$67,859.88	16,571
1/5/2026	Sell	1,566	$19.87	$31,116.42	12,982
1/3/2025	Sell	1,181	$17.37	$20,513.97	8,982

Charles O. Williams Buying and Selling Activity at Surrozen

Surrozen Company Overview

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Today's Range

Now: $23.39

$23.00

$25.13

50 Day Range

MA: $27.91

$20.69

$34.13

2 Week Range

Now: $23.39

$8.00

$35.00

Volume

71,099 shs

Average Volume

91,537 shs

Market Capitalization

$271.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51